All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
On July 19, 2022, Scientific Education Support held its first clinical trial club, entitled “BOREAS trial: Navtemadlin (KRT-232) vs best available therapy in relapsed/refractory MF.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, entitled “Novel agents for the treatment of advanced myelofibrosis.”
The live webinar aimed to discuss the phase II and phase III navtemadlin clinical trials (NCT03662126), investigating navtemadlin, a murine double minute 2 (MDM2) inhibitor, in patients with myelofibrosis (MF) who relapse on, or are refractory to, Janus kinase (JAK) inhibitors. The event was chaired by Laura Michaelis, Medical College of Wisconsin, Milwaukee, US, and presented by the trial investigator Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE.
During the webinar, Haifa Kathrin Al-Ali talked about MDM2 inhibition in MF, and presented safety and efficacy data from the phase II trial. Subsequently, the two speakers discussed what these findings, and the ongoing randomized controlled phase III BOREAS trial, mean for clinical practice, which was followed by a live Q&A session.
Clinical trial club: Navtemadlin vs best available therapy in relapsed or refractory myelofibrosis
What do the navtemadlin trials mean for clinical practice?
Overview of the navtemadlin trials (NCT03662126)
MDM2 inhibition in MF
Key phase II efficacy and safety findings
Novel agents to treat MF with suboptimal response to ruxolitinib: Combining ruxolitinib with navitoclax or KRT-232
Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway dysregulation is central to the pathogenesis of...
Phase II results from KRT-232, a first-in-class MDM2 inhibitor, for R/R MF failing JAK inhibitor therapy
Janus kinase (JAK) inhibitors (JAKi) are commonly used in patients with myelofibrosis (MF), however, more than half of patients may discontinue...
Subscribe to get the best content related to MPN delivered to your inbox